Literature DB >> 27264553

Endosomal acidic pH-induced conformational changes of a cytosol-penetrating antibody mediate endosomal escape.

Ji-Sun Kim1, Dong-Ki Choi1, Ju-Yeon Shin1, Seung-Min Shin1, Seong-Wook Park1, Hyun-Soo Cho2, Yong-Sung Kim3.   

Abstract

Endosomal escape after endocytosis is a critical step for protein-based agents to exhibit their effects in the cytosol of cells. However, antibodies internalized into cells by endocytosis cannot reach the cytosol due to their inability to escape from endosomes. Here, we report a unique endosomal escape mechanism of the IgG-format TMab4 antibody, which can reach the cytosol of living cells after internalization. Dissociation of TMab4 from its cell surface receptor heparan sulfate proteoglycan by activated heparanase in acidified early endosomes and then local structural changes of the endosomal escape motif of TMab4 in response to the acidified endosomal pH were critical for the formation of membrane pores through which TMab4 escaped into the cytosol. Identification of structural determinants of endosomal escape led us to generate a TMab4 variant with ~3-fold improved endosomal escape efficiency. Our finding of the endosomal escape mechanism of the cytosol-penetrating antibody and its improvement will establish a platform technology that enables a full-length IgG antibody to directly target cytosolic proteins.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antibody intracellular trafficking; Cytosol-penetrating antibody; Endosomal escape; Membrane pore formation; pH-dependent conformational change

Mesh:

Substances:

Year:  2016        PMID: 27264553     DOI: 10.1016/j.jconrel.2016.05.066

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  10 in total

1.  How Do Biomolecules Cross the Cell Membrane?

Authors:  Dehua Pei
Journal:  Acc Chem Res       Date:  2022-01-11       Impact factor: 24.466

Review 2.  Genetic and Covalent Protein Modification Strategies to Facilitate Intracellular Delivery.

Authors:  Justin M Horn; Allie C Obermeyer
Journal:  Biomacromolecules       Date:  2021-12-02       Impact factor: 6.978

Review 3.  Current progress in innovative engineered antibodies.

Authors:  William R Strohl
Journal:  Protein Cell       Date:  2017-08-18       Impact factor: 14.870

4.  Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.

Authors:  Seung-Min Shin; Dong-Ki Choi; Keunok Jung; Jeomil Bae; Ji-Sun Kim; Seong-Wook Park; Ki-Hoon Song; Yong-Sung Kim
Journal:  Nat Commun       Date:  2017-05-10       Impact factor: 14.919

Review 5.  Targeted Intracellular Delivery of Antibodies: The State of the Art.

Authors:  Tatiana A Slastnikova; A V Ulasov; A A Rosenkranz; A S Sobolev
Journal:  Front Pharmacol       Date:  2018-10-24       Impact factor: 5.810

6.  Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.

Authors:  Seung-Min Shin; Ji-Sun Kim; Seong-Wook Park; Sei-Yong Jun; Hye-Jin Kweon; Dong-Ki Choi; Dakeun Lee; Yong Beom Cho; Yong-Sung Kim
Journal:  Sci Adv       Date:  2020-01-15       Impact factor: 14.136

Review 7.  Strategies for the enhanced intracellular delivery of nanomaterials.

Authors:  Cláudia Azevedo; Maria Helena Macedo; Bruno Sarmento
Journal:  Drug Discov Today       Date:  2017-09-15       Impact factor: 7.851

Review 8.  Nanoparticles-Based Strategies to Improve the Delivery of Therapeutic Small Interfering RNA in Precision Oncology.

Authors:  Jinxing Huang; Kai Xiao
Journal:  Pharmaceutics       Date:  2022-07-29       Impact factor: 6.525

9.  RhoB blockade selectively inhibits autoantibody production in autoimmune models of rheumatoid arthritis and lupus.

Authors:  Laura Mandik-Nayak; James B DuHadaway; Jennifer Mulgrew; Elizabeth Pigott; Kaylend Manley; Summer Sedano; George C Prendergast; Lisa D Laury-Kleintop
Journal:  Dis Model Mech       Date:  2017-09-07       Impact factor: 5.758

10.  Intracellular delivery of therapeutic antibodies into specific cells using antibody-peptide fusions.

Authors:  Julie Gaston; Nicolas Maestrali; Guilhem Lalle; Marie Gagnaire; Alessandro Masiero; Bruno Dumas; Tarik Dabdoubi; Katarina Radošević; Pierre-François Berne
Journal:  Sci Rep       Date:  2019-12-10       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.